Caitlin John’s Pacira BioSciences PCRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$118K Hold
4,721
– – 0.06% 247
2026
Q2
$120K Buy
4,721
+337
+8% +$7.97K 0.07% 246
2026
Q1
$99.1K Buy
4,384
+180
+4% +$4K 0.06% 229
2025
Q4
$109K Sell
4,204
-1
-0% -$24 0.07% 223
2025
Q3
$108K Buy
+4,205
New +$103K 0.08% 178
2025
Q1
– Sell
-1,872
Closed -$35.3K – 599
2024
Q4
$35.3K Buy
1,872
+1,776
+1,850% +$31.2K 0.02% 282
2024
Q3
$1.58K Hold
96
– – ﹤0.01% 683
2024
Q2
$2.75K Hold
96
– – ﹤0.01% 618
2024
Q1
$2.8K Sell
96
-8
-8% -$246 ﹤0.01% 642
2023
Q4
$3.51K Buy
+104
New +$3.04K ﹤0.01% 616

Other funds holding PCRX

Caitlin John's PCRX Position: Q3 2026 in Review

Caitlin John held its Pacira BioSciences (PCRX) position steady in Q3 2026 at 4,721 shares worth $118K. The position accounts for 0.06% of the portfolio, ranked #247.

Caitlin John first reported a position in PCRX in Q4 2023 and has held it in 10 quarters since. The position peaked at $120K in Q2 2026. 258 funds tracked by Wall St. Rank hold PCRX as of Q3 2026.

  • Caitlin John held 4,721 shares of Pacira BioSciences worth $118K as of Q3 2026.
  • Caitlin John left its Pacira BioSciences share count unchanged in Q3 2026.
  • Pacira BioSciences made up 0.06% of Caitlin John's portfolio in Q3 2026, its #247 holding.
  • Caitlin John first reported a position in Pacira BioSciences in Q4 2023 and has held it in 10 quarters since.
  • Caitlin John's Pacira BioSciences position peaked at $120K in Q2 2026.
  • 258 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2026.

Based on Caitlin John's 13F filing for Q3 2026, filed 16 Nov 2026.